OSE Immunotherapeutics S.A.
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II c… Read more
OSE Immunotherapeutics S.A. (0RAD) - Total Assets
Latest total assets as of June 2021: €98.21 Million EUR
Based on the latest financial reports, OSE Immunotherapeutics S.A. (0RAD) holds total assets worth €98.21 Million EUR as of June 2021.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
OSE Immunotherapeutics S.A. - Total Assets Trend (2016–2020)
This chart illustrates how OSE Immunotherapeutics S.A.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
OSE Immunotherapeutics S.A. - Asset Composition Analysis
Current Asset Composition (December 2020)
OSE Immunotherapeutics S.A.'s total assets of €98.21 Million consist of 41.1% current assets and 58.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 30.3% |
| Accounts Receivable | €6.92 Million | 7.1% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €3.79 Million | 3.9% |
| Intangible Assets | €52.60 Million | 54.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2020)
This chart illustrates how OSE Immunotherapeutics S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OSE Immunotherapeutics S.A.'s current assets represent 41.1% of total assets in 2020, an increase from 40.8% in 2016.
- Cash Position: Cash and equivalents constituted 30.3% of total assets in 2020, up from 16.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 54.0% of total assets, a decrease from 58.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 54.2% of total assets.
OSE Immunotherapeutics S.A. Competitors by Total Assets
Key competitors of OSE Immunotherapeutics S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
OSE Immunotherapeutics S.A. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - OSE Immunotherapeutics S.A. generates 0.11x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - OSE Immunotherapeutics S.A. is currently not profitable relative to its asset base.
OSE Immunotherapeutics S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.64 | 2.82 | 1.89 |
| Quick Ratio | 2.64 | 2.82 | 1.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €27.45 Million | € 25.70 Million | € 18.45 Million |
OSE Immunotherapeutics S.A. - Advanced Valuation Insights
This section examines the relationship between OSE Immunotherapeutics S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.61 |
| Asset Growth Rate (YoY) | 9.0% |
| Total Assets | €96.97 Million |
| Market Capitalization | $59.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values OSE Immunotherapeutics S.A.'s assets below their book value (0.61 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: OSE Immunotherapeutics S.A.'s assets grew by 9.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for OSE Immunotherapeutics S.A. (2016–2020)
The table below shows the annual total assets of OSE Immunotherapeutics S.A. from 2016 to 2020.
| Year | Total Assets | Change |
|---|---|---|
| 2020-12-31 | €96.97 Million | +9.04% |
| 2019-12-31 | €88.93 Million | +15.64% |
| 2018-12-31 | €76.90 Million | -0.58% |
| 2017-12-31 | €77.35 Million | -13.62% |
| 2016-12-31 | €89.55 Million | -- |